Sodium Tetradecyl Sulphate

Sodium tetradecyl sulphate, often abbreviated STS, is a synthetic anionic surfactant, the sodium salt of a sulfated long-chain alcohol, with the molecular formula C14H29NaO4S. It is a white, water-soluble solid of relatively low toxicity that forms micelles in solution, the property that gives it its detergent action. Industrially it is prepared by treating tetradecyl alcohol with sulfur trioxide and then neutralizing the product with sodium hydroxide.

The compound's principal medical role is sclerotherapy, a procedure in which a solution is injected into an unwanted vein to make it collapse and disappear ^[1]. It belongs to the detergent class of sclerosants and is used across a range of dilute concentrations to treat everything from small cosmetic thread veins to larger varicose veins ^[1]. The agent can be delivered as a liquid or whipped with air or gas into a foam, a form that increases contact with the vessel wall; a large Cochrane review found sclerotherapy to be an effective and reasonably safe option for varicose veins, though it noted that the evidence comparing agents, concentrations, and foam versus liquid remains limited ^[2][3]. Beyond veins, it has been used off-label to sclerose and stabilize joints prone to recurrent dislocation.

Sodium tetradecyl sulphate is sold under brand names including Sotradecol in the United States and Fibrovein in the United Kingdom, Ireland, Australia, and several other countries, typically supplied in a set of standard concentrations ^[1]. It is a prescription-only medicine administered by a clinician through intravenous injection and is not available as a consumer product. Its regulatory classification places it among the sclerosing solutions used in vascular medicine.

Because the drug is injected into blood vessels, it is used only in a medical setting. Recognized risks include local reactions at the injection site, changes in skin pigmentation, formation of clots, and, less commonly, allergic reactions or deep vein thrombosis ^[1][2]. Careful technique and an appropriate concentration are used to limit these effects.

Sodium tetradecyl sulphate is prescription strength and given only by trained clinicians as an injection. Local effects include pain at the site, bruising, brown staining of the skin called hyperpigmentation and fine red vessels known as matting. More serious but uncommon risks are skin ulceration if the drug leaks outside the vein, blood clots that can travel to the lungs, and allergic reactions including rare anaphylaxis. Foam can send tiny bubbles into the circulation and has been linked to temporary visual disturbance, migraine and, very rarely, stroke, especially in people with a hole between the heart chambers. It is avoided in active deep vein clots and in people confined to bed.

Documented interactions for sodium tetradecyl sulphate are few, and that follows from how it is used: a detergent sclerosant injected directly into a vein, acting locally on endothelium rather than circulating as a systemic drug.

The clearest one is physical rather than pharmacological. Heparin and sodium tetradecyl sulphate are incompatible and are not combined in the same syringe, since the anionic detergent disrupts the heparin preparation.

The other concern is thrombotic. Sclerotherapy deliberately provokes clot formation in the treated vessel, and estrogen-containing oral contraceptives and other anovulatory agents independently raise venous thromboembolism risk; the combination has drawn caution in labeling despite the absence of controlled studies in that population. Systemic anticoagulation raises the mirror-image question, about bleeding at the injection site and about whether the intended sclerosis takes hold at all. Neither question has been settled by trial data, so both are handled on clinical judgment.

Checking a whole stack? Run it through interactions + stacks.

Sodium tetradecyl sulphate is a synthetic anionic detergent that has served as a sclerosing agent for the treatment of varicose and spider veins since the mid-twentieth century, with its introduction as a vein sclerosant dating to the 1940s. Its long clinical history predates the modern era of regulatory documentation, and it has been marketed for decades under brand names including Sotradecol in the United States and Fibrovein in the United Kingdom and other markets.

The compound works as a detergent sclerosant, disrupting the lining of the vein wall to provoke controlled scarring that closes the vessel. A major development in its use came with the popularization of foam sclerotherapy, in which the liquid agent is mixed with air or gas to create a foam that coats a larger area of vessel wall and displaces blood, improving effectiveness in larger veins. It remains a prescription-only injectable and one of the mainstays of sclerotherapy practice worldwide. Precise early corporate development details are not well documented in the modern literature.

Sodium tetradecyl sulphate is one of the most trusted and widely used sclerosing agents, backed by many decades of clinical experience in treating varicose and spider veins. Its detergent action reliably closes targeted veins, and the advent of foam preparations extended its usefulness to larger vessels while often reducing the amount of drug required. Practitioners value it as a minimally invasive, office-based alternative to surgery, with good cosmetic and symptomatic results for suitable veins. Systematic reviews support sclerotherapy as an effective option for many patients. Honesty requires noting that treatment can cause local effects such as bruising, pigmentation, or, uncommonly, more serious events, and that larger veins may need repeat sessions or other procedures. Within experienced hands and appropriate selection, it remains a dependable and enduring tool in vein care.